Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2018

  • ID: 4521342
  • Report
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Dare Bioscience Inc
  • Emotional Brain BV
  • EndoCeutics Inc
  • GlaxoSmithKline Plc
  • Palatin Technologies Inc
  • Pivot Pharmaceuticals Inc
  • MORE
Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2018, provides an overview of the Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline landscape.

Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses, such as chronic renal failure, hyper-prolactinaemia and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.

Report Highlights:

This latest pipeline guide Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Discovery stages are 1, 2, 5 and 1 respectively.

Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Dare Bioscience Inc
  • Emotional Brain BV
  • EndoCeutics Inc
  • GlaxoSmithKline Plc
  • Palatin Technologies Inc
  • Pivot Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Female Hypoactive Sexual Desire Disorder - Overview

Female Hypoactive Sexual Desire Disorder - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

GlaxoSmithKline Plc

Palatin Technologies Inc

Pivot Pharmaceuticals Inc

S1 Biopharma Inc

Female Hypoactive Sexual Desire Disorder - Drug Profiles

(buspirone hydrochloride + testosterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(sildenafil citrate + testosterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gepirone hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVT-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIP-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Hypoactive Sexual Desire Disorder - Dormant Projects

Female Hypoactive Sexual Desire Disorder - Product Development Milestones

Featured News & Press Releases

Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

Jan 09, 2018: Emotional Brain FSIAD Product Lybridos shows High Efficacy and Safety in Phase 2B Trials

Jan 09, 2018: Emotional Brain's FSIAD Product Lybrido shows High Efficacy and Safety in Phase 2B Trials

Mar 20, 2017: Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting

Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder

Sep 23, 2016: Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine

Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder

Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference

Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder

May 01, 2015: Emotional Brain Prepares for the Last Stage in Clinical Development of Medicines for Sexual Dysfunction in Women

Jul 29, 2013: S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD

Feb 20, 2012: S1 Pharma Submits IND Application For SIP-104 For Treatment Of Hypoactive Sexual Desire Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by Dare Bioscience Inc, H1 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, H1 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by EndoCeutics Inc, H1 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by GlaxoSmithKline Plc, H1 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies Inc, H1 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by Pivot Pharmaceuticals Inc, H1 2018

Female Hypoactive Sexual Desire Disorder - Pipeline by S1 Biopharma Inc, H1 2018

Female Hypoactive Sexual Desire Disorder - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Dare Bioscience Inc
  • Emotional Brain BV
  • EndoCeutics Inc
  • GlaxoSmithKline Plc
  • Palatin Technologies Inc
  • Pivot Pharmaceuticals Inc
  • S1 Biopharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll